Constellation Pharmaceuticals Lands $55,000,000 New Funding Round

  • Feed Type
  • Date
    12/10/2015
  • Company Name
    Constellation Pharmaceuticals
  • Mailing Address
    215 First Street Cambridge, MA 02142 USA
  • Company Description
    Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression.
  • Website
    http://www.constellationpharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $55,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    The Company plans to use the proceeds from the financing to advance its pipeline of direct tumor targeting and immuno-stimulatory epigenetic inhibitors, which includes its two wholly-owned, clinical-stage lead programs: a bromodomain and extra-terminal (BET) inhibitor as well as an EZH2 inhibitor, targeting difficult-to-treat cancers.
  • M&A Terms
  • Venture Investor
    Topspin Partners
  • Venture Investor
    Third Rock Ventures
  • Venture Investor
    The Column Group
  • Venture Investor
    Venrock
  • Venture Investor
    SR One
  • Venture Investor
    Undisclosed

Trending on Xconomy